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Sir,
Alefacept (Amevive; Biogen Idec, Cambridge, MA, 
USA) was the first biological agent to be approved in 
the USA for moderate to severe chronic plaque psoria-
sis (1). It is a fully human fusion protein, consisting of 
the first extracellular domain of lymphocyte function- 
associated (LFA)-3 protein fused to the hinge, CH2 and 
CH3 domains of human IgG1 (1, 2). Normally, LFA-3 on 
antigen-presenting cells and CD2 on T cells interact to 
provide a co-stimulatory signal that plays a major role in 
T-cell activation (2, 3). Alefacept blocks this interaction 
(1, 4). Furthermore, natural killer cells and macrophages 
recognize the Fc portion of the alefacept molecule that 
has bound CD2+ T cells, leading to apoptosis of mainly 
activated CD2+ and CD45RO+ T cells, key players in 
psoriasis (2).
Efficacy and safety of an intramuscular alefacept 
course of 12 weeks have been shown in at least two 
phase III studies. The PASI-75 and PASI-50, well-recog-
nized endpoints, were achieved by 28–33% and 53–75% 
of patients in these studies, respectively (5, 6). Compa-
rable results have been presented for patients with more 
severe psoriasis in which conventional therapies had 
already failed (7). A limitation of alefacept therapy for 
psoriasis is a delayed maximal therapeutic effect, often 
reached only after the active 12-week course (8). With 
a potent topical corticosteroid a good clinical result is 
generally achieved prior to 4 weeks of treatment (9–12). 
However, long-term efficacy of topical corticosteroids 
is limited by tachyphylaxis and rebound following 
discontinuation of treatment. We studied the effect of a 
combination of these two treatments for psoriasis.
METHODS
The present prospective, randomized, double-blind, placebo-
controlled, single-centre, explorative study included 16 patients 
with plaque psoriasis and compared the safety and efficacy of a 
12-week 15 mg intramuscular alefacept course vs. a combina-
tion of alefacept and topical betamethasone dipropionate cream 
(Diprosone®, Schering-Plough Amstelveen, The Netherlands), 
once daily, in the first 4 weeks of treatment. All patients recei-
ved alefacept, 8 were treated with betamethasone dipropionate 
cream, 8 with the vehicle cream alone (DiproBase®, Schering-
Plough), once daily, maximal 50 mg per week. Both groups 
underwent a 12-week follow-up period. Topical treatment alone 
had proven insufficient in our patient group. Patients had been 
treated with at least one systemic anti-psoriatic therapy in the 
past, which had either failed or was contraindicated at the time 
of inclusion. Further criteria were similar to standard clinical 
trials to assess efficacy and safety of biological agents. End-
points were safety and efficacy, determined by the following 
monthly assessed parameters: Psoriasis Area and Severity 
Index (PASI), quality of life (QoL), and self-reported psoriasis 
severity, determined using visual analogue scales (VAS), in the 
range 0–100, standard blood analysis, CD4+ T-cell count in 
peripheral blood and number and type of adverse events. Finally, 
the data were analysed with repeated measurement analyses of 
variance (ANOVA; Statistica®), where statistical significance 
was set at p < 0.05. 
RESULTS
Although the treatment regimens did not show statisti-
cally significant differences, both showed a time-related 
statistically significant improvement in PASI (p < 0.01) 
(Fig. 1). The maximal mean PASI reduction was 58% 
in the combination group vs. 84% in the monotherapy 
group (p > 0.05). At week 4 and 8, none of the patients 
achieved PASI-50 in the combination group, vs. one 
patient (13%) in the monotherapy group. At week 12, 
in the combination group, 2 patients (25%) achieved 
PASI-50, but none of them reached PASI-75. This result 
was sustained until 3 months after the last injection. 
In contrast, in the monotherapy group, already after 
4 and 8 weeks one patient (13%) had reached PASI-
50. At week 12, 3 patients (38%) achieved PASI-50 
and one of them reached PASI-75 at week 12. In 
this group even better results were achieved during 
3 months of follow-up: 4 patients (50%) achieved 
PASI-50 and 3 of them reached PASI-75. Self-assessed 
psoriasis severity showed similar improvements, with 
a non-significant difference between the treatments 
at week 12 and beyond. The results were slightly in 
Fig. 1. PASI score (Mean + SEM) during and after 12 weeks treatment with 
alefacept in combination with 4 weeks of betamethasone dipropionate cream 
(black columns) or the vehicle cream (grey columns).
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favour of the monotherapy group. The subjective 
scores correlated fairly well to the PASI (r = 0.41; 
p < 0.001). QoL results also showed a non-significant 
difference between the treatments at week 12 and during 
the follow-up phase. With both treatments QoL improved, 
again slightly in favour of alefacept monotherapy. The 
QoL scores correlated very well to the severity scores 
in each patient at the given time points (r = –0.32; 
p < 0.01), and to a lesser extent to the PASI (r = –0.09; 
p > 0.05)
Adverse events were mild and similar to those ob-
served in phase III and IV studies. No patients were 
withdrawn due to adverse events. In particular, infec-
tions were mild (e.g. common cold, viral laryngitis) and 
no doses were missed due to this. No clinically signifi-
cant changes were observed in vital signs, physical exa-
mination and standard blood analyses. Peripheral blood 
T-cell counts were generally reduced from baseline. 
Only in the combination group, one dose of alefacept 
was missed as a result of a reduction in CD4+ T-cell 
count below the limit. 
DISCUSSION
A statistically significant reduction in PASI scores 
was observed in both groups, treated with alefacept. 
Remarkably, the monotherapy group had more early 
responders, as well as long-term responders, than the 
combination group, although not statistically signifi-
cant. This effect was empowered by a larger number of 
patients in the monotherapy group that had reduction 
of their self-reported psoriasis severity, as well as im-
provement of their QoL. Both parameters correlated 
relatively well to disease severity. 
These results confirm the results of previous studies, 
regarding the clinical efficacy, effects on QoL and safety 
of alefacept monotherapy (5–8, 13–15). Potent topical 
corticosteroids have a broad range of effects on psoriatic 
plaques and most studies indicate a beneficial effect 
(9–12). Resistance to betamethasone dipropionate might 
be explained by tachyphylaxis, especially in our patient 
group, which had a long history of psoriasis and anti-
psoriatic treatments including topical corticosteroids 
(12). Relapse after cessation of topical corticosteroid is 
a second factor that may in part account for the results 
(10, 11). Increasing the dose of the topical corticoste-
roid, prolonged topical treatment or co-treatment with 
other anti-psoriatic medications are further options to 
increase the efficacy of alefacept therapy (12). 
In literature, and in the present study, there are clear-
cut inter-individual differences in response to alefacept 
therapy (5, 6). For the future, it might be a challenge 
to identify predicting factors for response to biologi-
cal agents in individual patients, prior to the start of 
treatment. 
In conclusion, a combination of alefacept with a 
corticosteroid cream for 4 weeks, once daily, did not in-
crease clinical efficacy and health-related QoL during a 
12-week course of intramuscular alefacept and beyond, 
as judged by both physician and patient.
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